Erratum: Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol

Erratum: Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol

Bibliographic Details
Main Authors:	Moumita Ghosh, Cecilia Galman, Mats Rudling, Bo Angelin
Format:	Article
Language:	English
Published:	Elsevier 2018-11-01
Series:	Journal of Lipid Research
Online Access:	http://www.sciencedirect.com/science/article/pii/S002222752030924X

Similar Items

LDL Cholesterol, Statins And PCSK 9 Inhibitors
by: Sanjiv Gupta
Published: (2015-09-01)

Monitoring hepatic cholesterol 7α-hydroxylase activity by assay of the stable bile acid intermediate 7α-hydroxy-4-cholesten-3-one in peripheral blood
by: Cecilia Gälman, et al.
Published: (2003-04-01)

Circulating Hepcidin-25 Is Reduced by Endogenous Estrogen in Humans.
by: Mikael Lehtihet, et al.
Published: (2016-01-01)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
by: Aureli Luquero, et al.
Published: (2021-03-01)

Potential of PCSK9 as a new target for the management of LDL cholesterol
by: Mombelli G, et al.
Published: (2015-07-01)

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
by: Schmidt, A, et al.
Published: (2019)

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
by: Amand F. Schmidt, et al.
Published: (2019-10-01)

Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9[S]
by: Sam J.L. van der Tuin, et al.
Published: (2015-11-01)

Legacy perfluoro-alkyl substances impair LDL-cholesterol uptake independently from PCSK9-function
by: Iva Sabovic, et al.
Published: (2023-12-01)

Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly
by: Ranheim Trine, et al.
Published: (2007-03-01)

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts
by: My-Anh Nguyen, et al.
Published: (2014-02-01)

Heparan sulfate proteoglycans present PCSK9 to the LDL receptor
by: Camilla Gustafsen, et al.
Published: (2017-09-01)

An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes
by: Liwen Zhang, Timothy McCabe, Jon H. Condra, Yan G. Ni, Laurence B. Peterson, Weirong Wang, Alison M. Strack, Fubao Wang, Shilpa Pandit, Holly Hammond, Dana Wood, Dale Lewis, Ray Rosa, Vivienne Mendoza, Anne Marie Cumiskey, Douglas G. Johns, Barbara C. Han
Published: (2012-01-01)

A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations
by: K Gadkar, et al.
Published: (2014-11-01)

Serum sdLDL-C and cellular SREBP2-dependent cholesterol levels: Is there a challenge on targeting PCSK9?
by: Soltanmohammadi Elham, et al.
Published: (2016-01-01)

Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population
by: Ilaria Guella, et al.
Published: (2010-11-01)

Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors
by: Øystein L. Holla, et al.
Published: (2011-10-01)

A virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in non-human primates
by: Alexandra Fowler, et al.
Published: (2023-09-01)

Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice[S]
by: Vikram Ravindra Shende, et al.
Published: (2015-04-01)

PCSK9 function and physiology*1
by: Andrew S. Peterson, et al.
Published: (2008-06-01)

Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations.
by: Mahtaab Hayat, et al.
Published: (2020-01-01)

PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE[S]
by: Brandon Ason, et al.
Published: (2014-11-01)

GRP94 Regulates Circulating Cholesterol Levels through Blockade of PCSK9-Induced LDLR Degradation
by: Steve Poirier, et al.
Published: (2015-12-01)

Circulating PCSK9 and Risk of Myocardial Infarction
by: Lars E. Laugsand, MD, PhD, et al.
Published: (2016-12-01)

Pcsk9 Deletion Promotes Murine Nonalcoholic Steatohepatitis and Hepatic Carcinogenesis: Role of Cholesterol
by: George N. Ioannou, et al.
Published: (2022-04-01)

Supplementation with Octacosanol Affects the Level of PCSK9 and Restore Its Physiologic Relation with LDL-C in Patients on Chronic Statin Therapy
by: Milica Zrnic Ciric, et al.
Published: (2021-03-01)

Correction: Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations.
by: Mahtaab Hayat, et al.
Published: (2021-01-01)

Editorial: PCSK9: Importance in Physiology and Pathophysiology
by: Rainer Schulz, et al.
Published: (2021-07-01)

PCSK9 - A New and Potent Approach to Lowering Cholesterol
by: Thomas F. Whayne Jr.
Published: (2013-05-01)

Cell-based, bioluminescent assay for monitoring the interaction between PCSK9 and the LDL receptor
by: Sarah J. Duellman, et al.
Published: (2017-08-01)

PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain
by: Mali Liu, et al.
Published: (2010-09-01)

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents
by: Troutt Jason S, et al.
Published: (2011-02-01)

PCSK9-mediated degradation of the LDL receptor generates a 17 kDa C-terminal LDL receptor fragment
by: Kristian Tveten, et al.
Published: (2013-06-01)

Circulating PCSK9 Linked to Dyslipidemia in Lebanese Schoolchildren
by: Yara Azar, et al.
Published: (2022-05-01)

PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
by: Preiss, D, et al.
Published: (2016)

Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
by: Farzahna Mohamed, et al.
Published: (2023-08-01)

PCSK9 inhibition and cholesterol homeostasis in insulin producing β-cells
by: Günter Päth, et al.
Published: (2022-12-01)

Of mice and men: murine bile acids explain species differences in the regulation of bile acid and cholesterol metabolism[S]
by: Sara Straniero, et al.
Published: (2020-04-01)

Sex difference in circulating PCSK9 and its clinical implications
by: Fang Jia, et al.
Published: (2022-09-01)

The predictive utility of circulating PCSK9 levels on diabetes mellitus
by: Jia Peng, et al.
Published: (2021-02-01)